TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type	
SIGA TECHNOLOGIES, INC.		12/31/2012	CORPORATION: DELAWARE	

RECEIVING PARTY DATA

Name:	GE Capital Equity Investments, Inc. c/o GE Healthcare Financial Services, Inc.
Street Address:	Two Bethesda Metro Center
Internal Address:	Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 6

Property Type	Number	Word Mark
Registration Number:	3703520	HUMAN BIOARMOR
Registration Number:	3729965	SIGA
Registration Number:	3703521	SIGA
Registration Number:	3723743	SIGA
Registration Number:	3719987	SIGA
Serial Number:	85568561	VARBLOCK

CORRESPONDENCE DATA

Fax Number: 2147581550

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Phone: 214-758-1500

Email: mecarter@pattonboggs.com

Correspondent Name: Margaret Carter

Address Line 1: 2000 McKinney Avenue, Suite 1700

Address Line 2: Patton Boggs LLP

TRADEMARK REEL: 004932 FRAME: 0196 OP \$165.00 3703520

900242777

Address Line 4: Dallas, TEXAS 75201								
ATTORNEY DOCKET NUMBER:	026674.0104							
NAME OF SUBMITTER:	Margaret Carter							
Signature:	/Margaret Carter/							
Date:	12/31/2012							
Total Attachments: 18 source=IP Security Agreement#page1.tif source=IP Security Agreement#page2.tif source=IP Security Agreement#page3.tif source=IP Security Agreement#page4.tif source=IP Security Agreement#page5.tif source=IP Security Agreement#page6.tif source=IP Security Agreement#page7.tif source=IP Security Agreement#page8.tif source=IP Security Agreement#page9.tif source=IP Security Agreement#page10.tif source=IP Security Agreement#page11.tif source=IP Security Agreement#page12.tif source=IP Security Agreement#page13.tif source=IP Security Agreement#page14.tif source=IP Security Agreement#page15.tif source=IP Security Agreement#page16.tif source=IP Security Agreement#page17.tif source=IP Security Agreement#page17.tif source=IP Security Agreement#page17.tif								

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Agreement"), dated as of December 31, 2012, is made by SIGA Technologies, Inc., a Delaware corporation ("Grantor"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative and collateral agent (in such capacity, together with its successors and permitted assigns, the "Agent") for the Agent and the Lenders (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan and Security Agreement, dated as of December 31, 2012 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), among Grantor, the other loan parties party thereto from time to time, the Lenders from time to time party thereto and GE Capital, as Agent for the Lenders, the Lenders have severally agreed to make Revolving Loans and a Term Loan (collectively, "Loans") to Grantor upon the terms and subject to the conditions set forth therein;

WHEREAS, pursuant to the Loan Agreement, Grantor is required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders and the Agent to enter into the Loan Agreement and to induce the Lenders to make the Loans to Grantor thereunder, Grantor hereby agrees with the Agent as follows:

- Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement.
- Section 2. Grant of Security Interest in Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, hereby mortgages, pledges and hypothecates to the Agent for the benefit of Lenders, and grants to the Agent for the benefit of Lenders a Lien on and security interest in, all of its right, title and interest in, to and under the following property of Grantor (the "Collateral"):
- (a) all Intellectual Property including, without limitation, those referred to on Schedule I hereto;
- (b) all licenses providing for the grant by or to Grantor of any right under any Intellectual Property, including, without limitation, those referred to on Schedule I hereto;
- (c) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals, reversions and extensions of the foregoing;
- (d) all goodwill of the Grantor connected with the use of, and symbolized by, such Intellectual Property; and
- (e) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

1

Notwithstanding the above, "Collateral" shall not include the Excluded Property (as defined in the Loan Agreement).

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Loan Agreement and Grantor hereby acknowledges and agrees that the rights and remedies of the Agent with respect to the security interest in the Collateral made and granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.

Section 5. Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

<u>Section 6.</u> Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

SIGA TECHNOLOGIES, INC., as Grantor

3y: <u>√√ ω</u>

Title:

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

026674.0104\4819-2823-5794

ACKNOWLEDGMENT OF GRANTOR

State of Way Sax ss.

County of John this day of December 2012 before me personally appeared which the foregoing instrument on behalf of SIGA Technologies, Inc., who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.

Notary Public

OFFICIAL SEAL NEZAR ABDUL-FATTAH NOTARY PUBLIC - NEW JERSEY MIDDLESEX COUNTY My Comm. Expires Mar. 13, 2013

ACCEPTED AND AGREED as of the date first above written:

as Agent

GENERAL ELECTRIC CAPITAL CORPORATION

Ву:

Name: Alan M. Silbert Title: Duly Authorized Signatory

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

026674.0104\4819-2823-5794

SCHEDULE I TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

Trademarks

(See Attached)

026674.0104\4819-2823-5794.3.

Trademark	Docket No.	Application No.	Registration No.	Trademark Status	Country	File Date	Reg. Date	Next Renewal Date
HUMAN BIOARMOR	SIGA-053	77/977,748	3703520	Registered	United States of America	21-Sep-2007	27-Oct-2009	27-Oct-2019
HUMAN BIOARMOR (Customs registration)	SIGA-057		TMK 09-01136	Registered	United States of America		01-Dec-2009	27-Oct-2019
SIGA	SIGA-027	2809653	2.421.717	Registered	Argentina	13-Mar-2008	28-Jan-2011	28-Jan-2021
SIGA	SIGA-028	1344770	1344770	Registered	Australia	13-Mar-2008	13-Mar-2008	13-Mar-2018
SIGA	SIGA-029	829690824		Opposed	Brazil	07-Apr-2008		
SIGA	SIGA-030	1386919		Allowed	Canada	11-Mar-2008		
SIGA	SIGA-031			Proposed	China (People's Republic)			
SIGA	SIGA-032	6780811	6780811	Registered	European Community	13-Mar-2008	03-Nov-2008	13-Mar-2018
SIGA	SIGA-045	301073231	301073231	Registered	Hong Kong	16-Mar-2008	16-Mar-2008	16-Mar-2018
SIGA	SIGA-033	1665309	1665309	Registered	India	17-Mar-2008	17-Mar-2008	17-Mar-2018
SIGA	SIGA-034	209494	209494	Registered	Israel	11-Mar-2008	11-Mar-2008	11-Mar-2018
SIGA	SIGA-042	40-2008-14092	40-789211	Registered	Korea, Republic of	21-Mar-2008	18-May-2009	18-May-2019
SIGA	SIGA-037	247875		OfficeAct	Pakistan	18-Mar-2008		
SIGA	SIGA-038	2008707332	402182	Registered	Russian Federation	13-Mar-2008	26-Feb-2010	13-Mar-2018
SIGA	SIGA-040	T0803130I	T08031301	Registered	Singapore	12-Mar-2008	12-Mar-2008	12-Mar-2018
SIGA	SIGA-041	2008/06387	2008/06387	Registered	South Africa	20-Mar-2008	30-Jul-2010	20-Mar-2018
SIGA	SIGA-043	97011593	1341359	Registered	Taiwan	17-Mar-2008	16-Dec-2008	16-Dec-2018
SIGA	SIGA-050	77/977,868	3729965	Registered	United States of America	21-Sep-2007	22-Dec-2009	22-Dec-2019
SIGA	SIGA-052	77/977,750	3703521	Registered	United States of America	21-Sep-2007	27-Oct-2009	27-Oct-2019
SIGA (AND DESIGN)	SIGA-059	1343869	1343869	Registered	Australia	03-Feb-2010	03-Feb-2010	03-Feb-2020
SIGA (and Shield Design)	SIGA-039	175205		Pending	Saudi Arabia	30-Nov-2011		
SIGA (and Shield Design)	SIGA-068	175206		Pending	Saudi Arabia	30-Nov-2011		
SIGA (and Shield Design)	SIGA-069	101005045	1541065	Registered	Taiwan	03-Feb-2012	01-Oct-2012	30-Sep-2022
SIGA (and Shield Design)	SIGA-051	77/977,869	3723743	Registered	United States of America	21-Sep-2007	08-Dec-2009	08-Dec-2019

A/75273858.1/3003495-0000323423

		Application	Registration					Next Renewal
Trademark	Docket No.	Application No.	No.	Trademark Status	Country	File Date	Reg. Date	Date
SIGA (and Shield Design)	SIGA-054	77/977,749	3719987	Registered	United States of America	21-Sep-2007	01-Dec-2009	01-Dec-2019
SIGA (Customs registration)	SIGA-056		TMK 09-01133	Registered	United States of America		01-Dec-2009	27-Oct-2019
VARBLOCK	SIGA-066	85/568,561		Allowed	United States of America	13-Mar-2012		

Patents

(See Attached)

026674.0104\4819-2823-5794.3.

SIGA List of Live Cases Worldwide

As of December 3, 2012

	As of December 5, 2012													
Country	Owner	Appin No	Filing Date	Publication No.	Publication Date	Patent No	Issue Date	Fille III	Status					
US	Siga Technologies, Inc.	11/791,926	18-Mar-2009	US-2009-0203675-A1	13-Aug-2009			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES	Published					
AU	Siga Technologies, Inc.	2005314252	06-Dec-2005		28-Jun-2007			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES	Allowed					
CA	Siga Technologies, Inc.	2,590,962	06-Dec-2005					COMPOUNDS AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES	Pending					
EP	Siga Technologies, Inc.	05852986.8	06-Dec-2005	1827446	05-Sep-2007			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES	Published					
JР	Siga Technologies, Inc.	2007-544594	06-Dec-2005	2008-524119	10-Jul-2008			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES	Published					
US	Siga Technologies, Inc.	11/653,972	17-Jan-2007	US-2010-0256096-A1	07-Oct-2010	7,994,221	09-Aug-2011	SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES	Granted					
CA	Siga Technologies, Inc.	2,674,967	16-Jan-2008					SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Pending					
EP	Siga Technologies, Inc.	08825856.1	16-Jan-2008	2124921	02-Dec-2009			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Published					
JP	Siga Technologies, Inc.	2009-546409	16-Jan-2008	2010-526025	29-Jul-2010			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Published					
AU	Siga Technologies, Inc.	2008257428	16-Jan-2008					SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Pending					

List of Live Cases Worldwide As of December 3, 2012

Country	Owner	Appin No	Filing Date	Publication No	Publication Date	Patent No	Issue Date	Title	Status
CN	Siga Technologies, Inc.	200880008297.9	16-Jan-2008	101641092	03-Feb-2010			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Published
MX	Siga Technologies, Inc.	MX/a/2009/07687	16-Jan-2008			994		SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Pending
US	Siga Technologies, Inc.	12/914,400	28-Oct-2010	US-2012-0022027-A1	26-Jan-2012			SEMICARBAZIDES AND UREAS PHARMACEUTICAL COMPOSITIONS	Allowed
US	Siga Technologies, Inc.	12/925,702	26-Oct-2010	US-2011-0118505-A1	19-May-2011			SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Published
WO	Siga Technologies, Inc.	PCT/US10/55086	02-Nov-2010	WO 2012/060820	10-May-2012			SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Published
US	Siga Technologies, Inc.	13/176,866	06-Jul-2011					SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS	Pending
US	Siga Technologies, Inc.	12/673,983	23-Nov-2010	US-2011-0064693-A1	17-Mar-2011			ARENAVIRUS INFECTION	Published
AU	Siga Technologies, Inc.	2008293532	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
CA	Siga Technologies, Inc.	2,698,075	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
CN	Siga Technologies, Inc.	200880104969.6	26-Aug-2008	CN101801189A	11-Aug-2010			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
EP	Siga Technologies, Inc.	08828765.1	26-Aug-2008	2182805	12-May-2010		**************************************	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
JP	Siga Technologies, Inc.	2010-523092	26-Aug-2008	2010-538000	09-Dec-2010			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
KR	Siga Technologies, Inc.	10-2010-7006853	26-Aug-2008	2010-00800516	08-Jul-2010			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
MX	Siga Technologies, Inc.	MX/a/2010/002278	26-Aug-2008		17-May-2010			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
ZA	Siga Technologies, Inc.	2010/01389	26-Aug-2008			2010/01389	24-Nov-2010	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
AP	Siga Technologies, Inc.	AP/P/2010/05172	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
OA	Siga Technologies, Inc.	1201000069	26-Aug-2008			14950	30-Dec-2010	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
BR	Siga Technologies, Inc.	Pi0815426-0	26-Aug-2008		99994 05.124 #423331#4333332#43335357-#433557-#433557-#433557-#4335			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending

SIGA List of Live Cases Worldwide As of December 3, 2012

Country	Owner	Appin No	Filing Date	Publication No	Publication Date	Patent No	Issue Date	Title	Status
SG	Siga Technologies, Inc.	201001040-3	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
VN	Siga Technologies, Inc.	1-2010-00409	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
IN	Siga Technologies, Inc.	1508/DELNP/2010	26-Aug-2008					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
SG	Siga Technologies, Inc.	Not available yet	26-Aug-2008	ANNO MANANJAMBO DA MARTINIA MANANDA MA				ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
US	Siga Technologies, Inc.	12/601,187	05-Apr-2010	US-2010-0189685-A1	29-Jul-2010			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	Published
CA	Siga Technologies, Inc.	2,688,194	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
EP	Siga Technologies, Inc.	08769679.5	23-May-2008	2148678	03-Feb-2010			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Published
JP	Siga Technologies, Inc.	2010-509565	23-May-2008	2010-528051	19-Aug-2010			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Published
ZA	Siga Technologies, Inc.	2009/08232	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
OA	Siga Technologies, Inc.	1200900399	23-May-2008			14767	30-Jun-2010	ANTIVIPAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Granted
AP	Siga Technologies, Inc.	AP/P/2009/05070	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
AU	Siga Technologies, Inc.	2008256727	23-May-2008	AND THE RESERVE OF THE PROPERTY OF THE PROPERT				ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
BR	Siga Technologies, Inc.	0810928-1	23-May-2008		23-Aug-2011			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	Published
CN	Siga Technologies, Inc.	200880017049.0	23-May-2008	101743008	16-Jun-2010			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Published
MX	Siga Technologies, Inc.	MX/a/2009/012299	23-May-2008		15-Jun-2010			ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Published
PH	Siga Technologies, Inc.	1-2009-502211	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
VN	Siga Technologies, Inc.	1-2009-02409	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION	Pending
IN	Siga Technologies, Inc.	7541-DELNP-2009	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
SG		201203757-8	23-May-2008	ranium (ranium recommende est emmane est estado de 1814 habitat (1816 habitat (1816 habitat (1816 habitat (1816				ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending
PH	Siga Technologies, Inc.	1-2012-502343	23-May-2008					ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGOE INFECTION	Pending

List of Live Cases Worldwide As of December 3, 2012

Country	Owner	Appin No	Filing Date	Publication No	Publication Date	a Patent No	Issue Date	Title	Status
US	Siga Technologies, Inc.	12/162,395	04-Nov-2008	US-2009-0180980-A1	16-Jul-2009	8,106,058	31-Jan-2012	ANTI-ARENAVIRAL COMPOUNDS	Granted
EP	Siga Technologies, Inc.	07769434.7	31-Jan-2007	1984379	29-Oct-2008			ANTI-ARENAVIRAL COMPOUNDS	Published
CA	Siga Technologies, Inc.	2,640,687	31-Jan-2007					ANTI-ARENAVIRAL COMPOUNDS	Pending
JP	Siga Technologies, Inc.	2008-553312	31-Jan-2007	2009-525338	09-Jul-2009			ANTI-ARENAVIRAL COMPOUNDS	Published
US	Siga Technologies, Inc.	13/339,478	29-Dec-2011					ANTI-ARENAVIRAL COMPOUNDS	Pending
US	Siga Technologies, Inc.	13/338,726	28-Dec-2011	US-2012-0107276-A1	03-May-2012		omercumanos en manos en escapa de diciones de 190 de naciones	ANTI-ARENAVIRAL COMPOUNDS	Published
US	Siga Technologies, Inc.	12/281,081	28-Aug-2008	US-2009-0036513-A1	05-Feb-2009	8,148,428	03-Apr-2012	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
US	Siga Technologies, Inc.	13/402,125	22-Feb-2012	US-2012-0149751-A1	14-Jun-2012			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
US	Siga Technologies, Inc.	13/402,167	22-Feb-2012					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
US	Siga Technologies, Inc.	11/712,918	02-Mar-2007	US-2007-0254934-A1	01-Nov-2007	7,872,037	18-Jan-2011	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
US	Siga Technologies, Inc.	12/111,778	29-Apr-2008	US-2008-0300265-A1	04-Dec-2008	7,977,365	12-Jul-2011	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
CA	Siga Technologies, Inc.	2,651,943	02-Mar-2007	ig appeal and the State Communication in the second control of the State Communication and the State Communication				ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
JP	Siga Technologies, Inc.	2008-557379	02-Mar-2007					ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
AP	Siga Technologies, Inc.	AP/P/2008/04594	02-Mar-2007			NACIONAL PROPERTY AND AN ARCHITECTURE AND ARCHITECTURE AN		ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
OA	Siga Technologies, Inc.	1200800307	02-Mar-2007	200		14273	31-Mar-2009	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted
ZA	Siga Technologies, Inc.	2008/07507	02-Mar-2007			2008/07507	26-Aug-2009	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted

List of Live Cases Worldwide As of December 3, 2012

Country Countr													
Country	Owner	Appin No	Filing Date	Publication No	Publication Date	Patent No	Issue Date	Title	Status				
US	Siga Technologies, Inc.	12/912,325	26-Oct-2010	US-2011-0172281-A1	14-Jul-2011			ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published				
US	Siga Technologies, Inc.	13/293,849	10-Nov-2011	US-2012-0071447-A1	22-Mar-2012			ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published				
GB	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
FR	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
DE	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
BE	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
T	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
ES	Siga Technologies, Inc.	07751991.6	02-Mar-2007	1988776	12-Nov-2008	1988776	08-Aug-2012	ANTI-VIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Granted				
US	Siga Technologies, Inc.	12/735,392	29-Sep-2010	US-2011-0027227-A1	03-Feb-2011			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Publishe				
AU	Siga Technologies, Inc.	2009232276	14-Jan-2009					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending				
CA	Siga Technologies, Inc.	2,712,071	14-Jan-2009					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending				

List of Live Cases Worldwide As of December 3, 2012

									le:
Country	Owner	Applin No	Filing Date	Publication No	Publication Date	Patent No	Issue Date	Title 1	Status
CN	Siga Technologies, Inc.	200980102314.X	14-Jan-2009	CN 101990434A	23-Mar-2011			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
EP	Siga Technologies, Inc.	09727680.2	14-Jan-2009	2240023	20-Oct-2010		w. et - c	ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
JP	Siga Technologies, Inc.	2010-543205	14-Jan-2009	2011-519346	07-Jul-2011			ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Published
MX	Siga Technologies, Inc.	MX/a/2010/06780	14-Jan-2009					ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION	Pending
US	Siga Technologies, Inc.	12/736,965	18-Mar-2011	US-2011-0158940-A1	30-Jun-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE	Published
AU	Siga Technologies, Inc.	2009256390	02-Jun-2009					SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Pending
CA	Siga Technologies, Inc.	2,726,985	02-Jun-2009					SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Pending
CN	Siga Technologies, Inc.	200980120810.8	02-Jun-2009	CN 102056483A	11-May-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Published
EP	Siga Technologies, Inc.	09759215.8	02-Jun-2009	2293671	16-Mar-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Published
JP	Siga Technologies, Inc.	2011-512578	02-Jun-2009	2011-522054	28-Jul-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUI VIRUS INFECTION	Published
MX	Siga Technologies, Inc.	MX/a/2010/013269	02-Jun-2009		16-Feb-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUI VIRUS INFECTION	Published
AP	Siga Technologies, Inc.	AP/ ² /2010/05480	02-Jun-2009					SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUI VIRUS INFECTION	Pending
OA	Siga Technologies, Inc.	1201000389	02-Jun-2009			15243	30-Jun-2011	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUI VIRUS INFECTION	Granted
BR	Siga Technologies, Inc.	0909985-9	02-Jun-2009		30-Aug-2011			SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUI VIRUS INFECTION	Published
SG	Siga Technologies, Inc.	201008370-7	02-Jun-2009		and to complete an organization and the state of the stat		general general production and the second se	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGU VIRUS INFECTION	Pending E
VN	Siga Technologies, Inc.	1-2010-03238	02-Jun-2009					SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGU VIRUS INFECTION	Pending E
lN	Siga Technologies, Inc.	8193/DELNP/2010	02-Jun-2009				inamentalismoni in managara m	SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGU VIRUS INFECTION	Pending E

List of Live Cases Worldwide As of December 3, 2012

Country	Owner	Appin No	Filing Date	Publication No	Publication Date	Patent No lissue Date	Title	Status
PH	Siga Technologies, Inc.	1-2010-502566	02-Jun-2009				TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Pending
IL	Siga Technologies, Inc.	209380	02-Jun-2009				SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Pending
НК	Siga Technologies, Inc.	11108398.8	02-Jun-2009	1153908A	20-Apr-2012		SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION	Published
US	Siga Technologies, Inc.	13/203,351	13-Oct-2011	US-2012-0022046-A1	26-Jan-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
CA	Siga Technologies, Inc.	2,753,421	24-Feb-2010				THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
AU	Siga Technologies, Inc.	2010218152	24-Feb-2010				THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
ZA	Siga Technologies, Inc.	2011/06270	24-Feb-2010				THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
MX	Siga Technologies, Inc.	MX/a/2011/008988	24-Feb-2010		11-Jan-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
EP	Siga Technologies, Inc.	107466743.3	24-Feb-2010	2400845	04-Jan-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
JP	Siga Technologies, Inc.	2011-552100	24-Feb-2010	2012-519174	23-Aug-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
CN	Siga Technologies, Inc.	201080016715.6	24-Feb-2010	CN102395273A	28-Mar-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
IL	Siga Technologies, Inc.	214825	24-Feb-2010				INHIBITORS OF DENGUE VIRUS	Pending
AP	Siga Technologies, Inc.	AP/P/2011/005901	24-Feb-2010	entralis per contralis contralis proposas de la proposa			INHIBITORS OF DENGUE VIRUS	Pending
OA	Siga Technologies, Inc.		24-Feb-2010				INHIBITORS OF DENGUE VIRUS	Pending
IN	Siga Technologies, Inc.	7358/DELNP/2011	24-Feb-2010				INHIBITORS OF DENGUE VIRUS	Pending
BR	Siga Technologies, Inc.	1005828-1	24-Feb-2010				INHIBITORS OF DENGUE VIRUS	Pending
KR	Siga Technologies, Inc.	10-2011-7022169	24-Feb-2010	2011-0136819	21-Dec-2011		INHIBITORS OF DENGUE VIRUS	Published
НК	Siga Technologies, Inc.	12104769.7	24-Feb-2010	1164053A	21-Sep-2012		THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published

SIGA List of Live Cases Worldwide As of December 3, 2012

Country	Owner	Applin No.	Filing Date	Publication No	Publication Date P	atent No Issue Date Title	Status
US	Siga Technologies, Inc.	13/379,776	21-Dec-2011	US-2012-0258079-A1	11-Oct-2012	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
AU	Siga Technologies, Inc.	2010266570	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
CA	Siga Technologies, Inc.	2,763,194	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
CN	Siga Technologies, Inc.	201080029400.5	22-Jun-2010	102469788A	23-May-2012	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
EP	Siga Technologies, Inc.	10794556.0	22-Jun-2010	2448410	09-May-2012	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
HK	Siga Technologies, Inc.	12104770.4	15-May-2012	1164054A	21-Sep-2012	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
JP	Siga Technologies, Inc.	2012-517646	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
KR	Siga Technologies, Inc.	10-2011-7030640	22-Jun-2010	2012-0049852	17-May-2012	TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Published
MX	Siga Technologies, Inc.	MX/a/2011/012983	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
BR	Siga Technologies, Inc.	1003034-7	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
IN	Siga Technologies, Inc.	10232/DELNP/2011	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
IL	Siga Technologies, Inc.	216805	22-Jun-2010			TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS	Pending
WO	Siga Technologies, Inc.	PCT/US11/25356	18-Feb-2011	WO/2011/103375	25-Aug-2011	INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS	Published
US	Siga Technologies, Inc.	13/578,413	10-Aug-2012	and the second		INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS	Pending
EP	Siga Technologies, Inc.	11745286.2	18-Feb-2011			INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS	Pending
US		61/600,036	17-Feb-2012			ANTIVIRAL DRUGS FOR TREATMENT OF ARENVIRUS INFECTION	Pending

Copyrights

NONE.

026674.0104\4819-2823-5794.3.

TRADEMARK **REEL: 004932 FRAME: 0215**

RECORDED: 12/31/2012